The combination of HER2‐targeted therapy with PD‐1/PD‐L1 inhibitors has demonstrated synergistic effects in cancer treatment, primarily due to their combined modulation of the immune microenvironment and tumor cells. This evidence concerns the gene PDCD1 and neoplasm.